RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
Public ClinicalTrials.gov record NCT05883631. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Prospective, Single Arm, Multi-center, Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-pulmonary Vein Sources of Atrial Fibrillation and Guide Ablation Therapy.
Study identification
- NCT ID
- NCT05883631
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Lead sponsor
- Cortex
- Industry
- Enrollment
- 400 participants
Conditions and interventions
Conditions
Interventions
- Electrographic Flow (EGF) mapping and ablation of EGF-identified sources of Atrial Fibrillation Device
- Electrographic Flow (EGF) mapping (no ablation) Device
Device
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 22, 2023
- Primary completion
- Dec 31, 2025
- Completion
- Dec 31, 2025
- Last update posted
- Apr 12, 2025
2023 – 2026
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama | Birmingham | Alabama | 35233 | — |
| Grandview Medical Center | Birmingham | Alabama | 35243 | — |
| Banner Health | Phoenix | Arizona | 85006 | — |
| Sutter Health Sequoia Heart and Vascular Institute | Redwood City | California | 94062 | — |
| Pacific Heart Institute | Santa Monica | California | 90404 | — |
| Colorado Heart | Golden | Colorado | 80402 | — |
| Florida Heart Rhythm Specialists | Fort Lauderdale | Florida | 33308 | — |
| Ascension Medical Group | Jacksonville | Florida | 32204 | — |
| Piedmont Health | Athens | Georgia | 30606 | — |
| Beaumont Health | Royal Oak | Michigan | 48073 | — |
| Mount Sinai Hospital | New York | New York | 10029 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| University of Virginia | Charlottesville | Virginia | 22908 | — |
| Inova Health | Falls Church | Virginia | 22042 | — |
| Evergreen Health Research/Overlake Medical Center | Bellevue | Washington | 98004 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05883631, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2025 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05883631 live on ClinicalTrials.gov.